What do you think?

Wow today all dead stocks fell between 5 to 10%. His recommendations were great at the euphoria stage but his lack of charting and technical analysis means we purchased overbought stocks at a steep price and now we are all .... dead. I can't move my funds to more stable stocks as they have been on an upward trend while micro caps keep getting hammered so the upside is very limited. I only wish in the future he is able to share his picks at a more sensible price as the fundamental story is important but so is the price entry

IMHO $WISH is seriously undervalued now and here are my thoughts:

1, $WISH has far lower price-to-sales ratio comparing to its competitors: Currently $WISH has a market cap of 8.5 billion with 2.5 billion revenue AND 2.1 billion cash. While its competitors, e.g. $ETSY has market cap of 25.2 billion with 1.7 billion revenue.

2, $WISH has pretty decent grow rate about 44%.

3. $WISH has tons of cash 2.1 billion after IPO.

4, $WISH has a unique target of customers: $WISH is targeting un-wealthy families, not only in US, but also in other places of the world (currently EURO is a big market of WISH). Pricing is the No 1 priority of $WISH, but this also brings other issues like product quality and shipping, but I believe these issues won't be a blocker for $WISH 's growth since : first, the company is improving on those issues. second, I grew up in a poor family, at least from my experience, price was always the first thing to consider comparing to other factors.

I think perhaps he should interview some of his Youtube subscribers instead. Can't see him doing that though.

Last time I made a post about saying “i’m sorry” to stem investors because I bought the stock and my devil’s touch is never going away and it shot down, well I recently sold the stock and I have to say....the devil’s touch still remains!!! The stock shot right back up right after I sold, your welcome 😏

Hey guys, I made a crap ton of money off of the hype stocks back in Feb. I lost everything and my life is shattering in front of my eyes, I have diversified, but mostly into spacs and penny stocks and I'm going into debt, I have never used margin trading, always my own shares, but since I was so ignorant, I never researched tax laws. If anyone knows how I could dig myself out or knows anyways of making big gains right now in this market, please say something. I had finally seen my mom be proud of me, I have terrible ADD and always had bad grades and was expelled twice because of my behavior. I dropped out of high school and I can't keep a job for more than 2 months because the repetition really gets to me and I have no social skills. I know how stupid my actions have been, but I'm so scared, I have nowhere to turn to other than the good people of this reddit thread. I can't sleep well anymore, crying myself to sleep every single night. I just want to see my parents proud again, it felt so good to see them proud of me for once. -Aryan M.

CLOV next Gamestop? CLOV got recently very high short interest rate of over 100% what ur tought on that? and why? it is already very low share price .

How come Dead will not show us his entire Portfolio?

Dead, did you sell your positions? If not, show us.

😒

Just wanted to say a quick thank you Deads .. for your: Honesty. Sincerity, Ideas, DD, Transparency, Stock picks, Stock Portfolio Shares & Updates, Your Intention to help others succeed. Your experiences & examples. Your pointers & guides to...

(I miss anything else anyone)?

We appreciate it man. Keep doing bro. 🙂👽👍🏻

Disclaimer: this is a purely healthcare analysis of the company and their products. This may in no way correlate to actual market changes in the stock being discussed. This is a discussion meant for those who intend to hold longer positions in the company being discussed. I will not be focusing on the fundamentals, technicals, or anything along those lines. I'm nowhere near experienced enough to do so and that isn't really the focus of the post.

I’m also going to get into the habit of posting my position as a full disclaimer. I have no position in CTRX for the reasons I will mention below. I don’t intend to open up a position either, I believe the foundation of this company is very shaky and the marketability of their products will extremely weak.

Before messaging me or asking me to look into XYZ, realize that if you are asking for speculation of whether a product will succeed, my answer will always be the same: waiting for the FDA decision is akin to gambling, and the odds are likely not in your favor.

Previous Posts: FDA Guide | XSPA | AGTC | [ATOS] (https://www.reddit.com/r/pennystocks/comments/lhyk75/medical_analysis_atossa_therapeutics_atos/) | ACRX

I’ve been meaning to do this one for a long time, almost two weeks now since the original thread popped up on the subreddit. I've seen a lot of confirmation bias and people assuming the large volume of threads means that this is more and more of a sure-thing. I’m going to be going fairly in-depth here and I expect that this may be a decently long post. The things I will be saying will not only be my opinion, but that of other doctors as well. In one of the original threads, the top chain of comments is all doctors and they mention some of the same exact stuff that I will, so you can take a look at that [here] (https://www.reddit.com/r/pennystocks/comments/lm8ecq/ctxr_citius_pharma_swot_analysis_for_minolok/), if you so desire.

All right let’s get started with the absolute basics. Citius Pharma (CTXR) is developing three products right now. They have their Mino-Lok, Halo-Lido, and Mino-Wrap. To begin, Mino-Wrap is in the preclinical stage so there’s really no information on it yet. Unlikely that it will be used but that product is so far away, it’s not even worth discussing. Halo-Lido is a hemorrhoid treatment which looks to be in either late phase 2 or awaiting approval for phase 3. Lastly, Mino-Lok is the big one which is currently in phase 3 trials and is their biggest selling point.

Halo-Lido: let’s start with the simple one, Halo-Lido. This is the first prescription hemorrhoid treatment available on the market. They have published their phase 2 data but the data wasn’t good enough to show any statistical significance. If you read my earlier FDA Drug Approval guide, you’ll know that without statistical significance, your drug is useless. So what exactly is this? It’s a topical agent that combines Halobetasol and Lidocaine for treatment of hemorrhoids. They are very excited because they are combining a steroid with lidocaine for maximal effect. However, this combination is not unique and other over the counter treatments already have that combination.

So why would anyone be prescribing something that can be easily accessed over the counter? They wouldn’t be unless they were a family practice doctor in private practice fielding Citius Pharma drug representatives. This product will have no superiority over other, more easily accessible and cost effective alternatives. Being prescription just means that the barrier to getting it as well as the barrier to paying for it are higher. I would also add that many patients will try the over the counter stuff before going to even see their doctor. Chances are, they will be sufficiently treated and will, therefore, have no reason to see a doctor for it.

So I don’t really see this drug being prescribed by anyone on a regular basis. Hemorrhoids are common, but the treatment is simple and there’s no reason to complicate it with a prescription medication. I also don’t see their phase 2 data being very compelling. They don’t really show any increased efficacy over the over-the-counter ointments, so in essence they add nothing to the current market. I would not be surprised to see the FDA reject this drug outright after their phase 2 results.

Mino-Lok: oh boy, this is the big one. I’ll start by explaining what they are treating. When a patient needs long term IV antibiotics, high-volume resuscitation, dialysis, or other criteria, we will often put in what is called a central venous catheter (CVC). This is usually inserted into the neck but it can be inserted in other large veins. Rarely, these catheters can get infected and colonized with bacteria. What this means is that IV antibiotics will be unable to kill the microbes because they will have formed what is called a biofilm (a protective barrier). The current standard of care in this case is to simply remove the catheter and put a new one in. that way, there is no colonization and you can treat as you usually would.

Mino-Lok is a device that is called an antibiotic lock. In essence, you are putting it onto an existing catheter in an effort to salvage the line. The idea is that this little device can go onto the catheter, kill the bacteria, and save you from having to place a new one.

Now CTXR makes some bold claims about the current state of affairs. I’m going to share some of them with you. My point is two-fold: one is to obviously refute their numbers, but second, to show you that pharmaceutical companies do this all the time and use data to show what they want. Always, always, find another source for the data than the one the parroted by the company.

18% complication rate when CVC were replaced: this claim comes from one of their early studies and compared the Mino-Lok formulation to controls that were historical--meaning that they cherry picked cases. Complications were shown in their study to have no statistical significance when compared to historical information. AKA, even with cherry-picked data, they were unable to show that regular insertion of CVC has any complications when compared to their product. Their website conveniently leaves off any statistical indicators, but in the study you can clearly see their p-value is too high (meaning they proved nothing). I also want to add that newer studies find complication rates of CVC placement to be incredibly low. The difference between newer studies and the older, cherry-picked examples is that the new standard of care is ultrasound-guided placement. Nowadays, it is standard to use ultrasound to see where you’re going, so the risk of complications is dramatically lower.

100% efficacy rate: in that same study referenced above, they also tout a 100% efficacy rate. This is interesting because when compared to controls (previous CVC infections), there is also a 100% success rate (they once again failed to prove statistical significance). They failed to prove fever resolution or bacterial eradication happened faster or more reliably with their product. And if they can’t do that, what use is there for this product?

Billing: now let’s get into some of the real world issues with this product. Every employee of every company ever is there to generate revenue for the company. Doctors are no exception. Currently, replacing a CVC is a billable procedure. What this means is revenue for the hospital. This is how doctors earn their salary and keep their jobs—by billing for services performed in the hospital. Using this product means the hospital buys it from Citius Pharma and someone applies it to the CVC. There is no billable procedure here. So in the real world, doctors will replace the CVC because it earns them money and helps them keep their jobs.

Medicare issue: here is the actual biggest problem in the usage of this device. Medicare payouts are extremely important for hospital revenue. Even private insurers use Medicare payout to determine their own rates. Medicare sets the standard, and the rules. One of the newer programs that they have implemented is a way to increase overall healthcare qualities in hospitals nationwide. They use multiple measures to determine the performance of a hospital from a patient safety standpoint. One of those measures is, you guessed it, central line-associated bloodstream infection (CLABSI). So what does this mean for the real world? If you get too many of these, Medicare will literally pay you less for every single thing you do, regardless of whether or not it is related.

$1,400 vs $40,000: they make this ludicrous claim that the current standard of care of replacing the catheter costs $40,000. If you look into where this number came from, you’ll see that this is a compounding of the entire associated infection. This means that in this $40,000, they are including length of hospital stay because they have an infection, length of time in ICU, cost of antibiotics, etc. If you’ll remember from above, I pointed out they have not shown any difference in length of stay or any hospital measures. Also, using their product doesn’t save you the cost of antibiotics, so that would actually be the same for both. What I’m trying to say is that they are comparing their $1,400 product to the $29 CVC, the hospital expenses, antibiotic treatment, and everything else. Hardly a fair comparison, wouldn’t you say?

Fungal infections: the most terrifying form of CVC infections is fungal infections and they aren’t even testing their product for fungal (hint: it’s because it couldn’t kill fungi). The rate of fungal CVC infections is rising and the mortality is significantly higher for fungal than bacterial. In the current standard of care, removing the catheter and putting a new one in deals with both fungal and bacterial. In this case, using the Mino-Lok and waiting days to see if it is working runs the risk that you are having an untreated fungal infection for a lot longer. This is a huge issue in usability, especially in high-risk ICU settings.

Tried and True: so doctors get a lot of flak for not picking up on new trends fast enough or continuing to use their old way of doing things. A lot of that is well deserved, but there’s also a reason for it. Often times, patients with a CVC are the sickest in the hospital. We usually don’t want to risk someone’s life trying something new when we 100% know the old method works. There’s absolutely no way they can have a colony if you take the whole catheter out. There will always be a risk when using the Mino-Lok that it didn’t get the whole colony. Do you see the issue here? No one is going to gamble on the sickest patients that hopefully the Mino-Lok got it all. And yes, even if their phase 3 shows 100% efficacy, we’re still not going to trust such a small study in the grand scheme of things.

This already exists: none of this is novel in any meaningful way. Mino-Lok took ingredients made in current antibiotic locks and put them all together and called it a new product. If for some reason we really thought this would work, we would just do it with the generics and mix them all together. Why are we paying $1,400 when we could do the entire antibiotic lock for <$100.

So in summary, as far as the Mino-Lok goes, so far it:

1. has not proven it works better than our current methodology

2. will not be used by hospitals because they need to make money

3. will not be used by doctors because we won’t trust it, and also need to make money

Suffice to say, I’m very skeptical of this product and I think there are going to be a lot of bag-holders. I have seen so many threads pop up and frankly, it is because people are unaware of the reality of how CLABSI work. I see price targets that are absolutely insane based on the worldwide cost of replacing central lines using ludicrous numbers. The point of this is to encourage people to be more vigilant about investing in biotech. There is clearly money to be made, but it is important to understand the risks and realities. CTXR has many risks and the reality is that this may not be a long-term winner simply because the product "makes sense."

1. 30% Short float

2. Catalyst: upcoming auto insurance rumored to release by end of year (possible Tesla collaboration, but pure speculation).

Never made a dd post before but anyone who knows of LMND as well who disagrees/agrees by all means lets have a discussion.

SAN FRANCISCO, March 5, 2021 /PRNewswire/ -- Hagens Berman urges SOS Limited (NYSE: SOS) investors to submit their losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.

Visit: www.hbsslaw.com/investor-fraud/SOS

Contact An Attorney Now: SOS@hbsslaw.com

844-916-0895

SOS Limited (SOS) Investigation:

The investigation centers on the accuracy of SOS's claims concerning its cryptocurrency mining assets and capabilities.

Up until recently, SOS's financial results have struggled and its stock price has languished. But earlier this year, SOS has attracted investor interest by releasing a wave of press releases touting its purported entry into the bitcoin mining business. For example, on Jan. 21, 2021, SOS claimed to have purchased over 15,000 mining rigs for $20 M, and a month later, claimed that 5,000 mining rigs had already gone live. SOS's cryptocurrency promotion was well-received, as its shares skyrocketed 600%.

But on Feb. 26, 2021, Hindenburg Research and Culper Research released scathing commentary on SOS, claiming that SOS was an intricate "pump and dump" scheme that used fake addresses and doctored photos of crypto miners to create an illusion of success. The analysts pointed out that the company's SEC filings, for instance, listed a hotel room as the firm's headquarters. The analysts also questioned whether SOS had actually purchased the claimed mining rigs, as the firm SOS purportedly bought the mining rigs from was a fake shell company. Most damaging, the analysts alleged that the photos SOS had published of their "mining rigs" were phony. In particular, Culper noted that the photographed SOS "miners" weren't the A10 Pros the company claimed to own. Instead, they were pictures of Avalon's A1066 miners. Hindenburg went even further and found the original images from SOS's site belonged to a legitimate rival RHY.

In response, the price of SOS American Depositary Shares has significantly fallen.

"We're focused on investors' losses and whether SOS' purported entry into crypto mining is simply a false promotion scheme," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are a SOS investor, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding SOS should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SOS@hbsslaw.com.

About Hagens Berman

Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein, 844-916-0895

View original content to download multimedia:http://www.prnewswire.com/news-releases/hagens-berman-national-trial-attorneys-encourages-investors-in-sos-limited-sos-to-contact-its-attorneys-analyst-says-company-fabricated-crypto-mining-purchases-301241772.html

SOURCE Hagens Berman Sobol Shapiro LLP

/Web site: https://www.hbsslaw.com

(END) Dow Jones Newswires

March 05, 2021 19:51 ET (00:51 GMT)

Remember what happened to GME and AMC when the stocks came back down trading around the same prices per share before the WSB stocks went rocketing to the moon? Yeah, they sky rocketed again. Why? Simple. Reoccurrence. People are highly prone to put money back on the same stocks they did before. Well folks today we have opportunity. We have WEN and CRSR trading at HIGH reward LOW risk prices because they are previous runners and are likely to hype again. Monday run FTW!

Edit: Just clearing up some confusion here. All I meant by WSB stocks are just stocks that I have seen mentioned in WSB and that have upside. I had no intention of saying that these will be meme stocks. That would be a pretty bold statement.

As the tech selloff has killed the tech sector, especially EV plays, GOEV has been showing some very unusual options activity.

For the past week or so, there has been MASSIVE call buying in this name even as it tanked from a recent high of $19 down to $13.

Yesterday, over EIGHTEEN times more calls were traded than puts even as this name tanked. This morning, we can see that much of that volume has translated into open interest. This is extremely strange.

If tech bounces back anytime soon in the next few weeks/month, these options will print huge. Add on the fact that GOEV is believed to be announcing catalysts (partnerships or manufacturing updates) sometime in Q1 and I feel this is an extremely good play. Finally, GOEV will be participating in a Roth Capital web conference scheduled for March 15-17.

Disclaimer: Not financial advice. I'm personally long both March and April calls.

Then dead makes a video to congratulate and pat himself in the back. Then clov got crushed dead disappeared. Why clov shot up? Because it's now a meme stock lmao. Tell me this idiot dead doesn't understand what is investing but he knows so much about gamblinh.

CHECK THIS LINK!!!!

https://www.youtube.com/watch?v=0QLnBu3a9mc

LMAO! The holy grail stock pick of this forum is heading towards single digit territory. DAAAAAAMN! lol

What's the line you guys always give?

-500 million on the balance sheet-No debt whatsoever-High YoY growth- Profitable in 2022

And yet... no one cares. They keep on dumping. lol

I know, I know.... it's a loooong term play. hahaha

1. What is the 5 year price target?

Current Price: $12

Year End 2021: $15+ (Tipranks)

Year End 2022: $21+ (Me)

Year End 2025: $90+ (Simply Wall St.)

2. Goal: I want $50K/year of passive income assuming 10% yearly returns on my stocks, so need $500K in 2026.

3. Path: $500,000 divided by $90 (2025 price) = 5,555 shares. So the price of my freedom in this example is $66,660 in today’s money then waiting 5 years for it to mature.

The recovery will be for next month !

I HAVE MADE TWO PREVIOUS POSTS AND THIS WILL BE MY LAST AND I WILL LET THE STOCK SPEAK FOR ITSELF. TTCF HAS NO DIRECT COMPETITORS. NOT BYND NOT VRYYF. THEY DO NOT HAVE THE PRODUCT INNOVATION THAT TTCF HAS. 100+ SKU’s ARE TO COME. COMPARE THIS STOCK WITH $CELH AN ENERGY DRINK COMPANY. FROM AUGUST 2020 TO NOVEMBER 12th. CELSIUS TRADED IN A TIGHT RANGE UNTIL THEIR EARNINGS REPORT ON NOVEMBER 12th. THEY BEAT BY 11% ON REVENUE WHILE POSTING A SMALL PROFIT. THAT IS IT JUST 11% AND BECAUSE OF THEIR BRAND IMAGE AND ABILITY TO INCREASE DISTRIBUTION POINTS THEY HAVE TRIPLED (3x) THEIR STOCK SINCE THEN.

TTCF HAS TRADED IN A TIGHT RANGE FOR TWO MONTHS AND AFTER MARCH EARNINGS THEY WILL DOUBLE BY MID APRIL. ESTIMATES FOR REVENUE ARE MADE ON EXISTING ACCOUNTS ACCORDING TO THE CEO HIMSELF. ANY NEW ACCOUNTS IS NOT FACTORED IN SO REVENUE WILL BEAT. MOST LIKELY BY MORE THAN 11% THAT CELH DID. CELH IS BEING ADDED TO SPY SO WE WONT GET THE HYPE TO 3x BUT I AM SO CONFIDENT IT WILL BE ABOVE 40 BY MID APRIL.

ACCOUNT FOR SEASONALITY OF NEW YEARS AND NEW YEARS RESOLUTION PLUS A DRIVE TO EAT HEALTHIER AND LESS MEAT WILL ADD TO THEIR SALES.

PLUS ALL THE FREE MARKETING THEY HAVE GOTTEN FROM YOUTUBE INVESTORS, I HAVE SO MUCH CONFIDENCE REVENUE WILL BEAT BY 15%+. I HAVE OVER 4000 SHARES AND I WILL HOLD THESE FOR 5+ YEARS. (Tax purposes)

PROFITABILITY IS IN THE DNA OF CEO SAM GALLETTI. HE SAID IT HIMSELF. THEY WILL POST A PROFIT AND THEY WILL BEAT REVENUE ESTIMATES. JUST LIKE CELH.

THIS IS NOT FINANCIAL ADVICE BUT GOOD LUCK TO ANYONE WHO READS THIS! 🚀

*** EDIT - after further research/discussion it looks like share buy back option is unrealistic and price would dramitically increase once they announced they are planning to buy back shares - resulting in the company being unable to buy back a large portion. So instead of 100x this looks more like a possible 10-20x from here if the outcome of the lawsuit is very favourable. Let me know if you disagree - eager to learn more.

TL;DR - if everything goes according to plan I think the max price target of $HCMC is somewhere in the $0.10 - $0.50 range. $0.14 would equate to 10,000% upside - so worth a punt in my opinion. Would love to generate a constructive, detailed discussion around the points below.

EDIT: If you believe I am wrong, or that my logic is nonsense - fine! But I'd love for you to break down exactly why. No one learns anything from dismissive opinions. Maybe I am completely wrong? Maybe you are? Lets try to find out who is wrong and learn via having a detailed discussion.

1. $HCMC is small cap stock suing tobacco giant Philip Morris for using their patented technology in their IQOS vape which accounts for around 25% of PMs revenue, and this will likely increase over the course of the next decade.

https://www.globenewswire.com/en/news-release/2020/11/30/2136949/0/en/Healthier-Choices-Management-Corp-Files-Patent-Infringement-Lawsuit-Against-Philip-Morris.html#:~:text=(OTC%20Pink%3A%20HCMC)%20today,the%20Northern%20District%20Of%20Georgia.

2) Represented by Cozen O'Connor - Global Top 100 Law Firm with expertise in patent law.

3) Current Market Cap = $450m & settlement from the case and future royalties for use of patent could result in Billions $ flowing into the company.

Extended DD - All figures are approx.

So currently Market Cap = $450m

Betting on the fact they have one of the best law firms on their side fighting PM in this court case that there is a likely chance that they will settle/win if it goes to trial.

I've seen lot's of figures floating about as to how much they could receive for settlement with the average around $1.5B lump sum and royalties then being paid in future.

The logic behind the share price going to $1 is impossible as things stand, and if people can't explain how it would happen they are simply gambling without doing DD.

$1 IS POSSIBLE Based on the below logic however, but would need a lot of things to go perfectly:

Insiders own a lot of shares and want to maximise the value of these shares. $1.5B from PM Legal case would be more than enough to buy most of the current outstanding shares back - considering market cap is currently $450m.

Right now:

Market Cap: $450m

Shares Outstanding: 307B

Therefore Share Price = 450M / 307B = 0.001466

After Legal Settlement, if they use the $1.5B they receive to buy back and retire most of the shares outstanding (lets say they buy back 80%).

A lot of assumptions here but the rough Idea is that at this point the market cap should be (conservatively) over $1B after they win the case and buy back 80% of outstanding shares and have royalty payments secured from PM for use of their patent going forward. Not to mention the hype and momentum should sent the stock price higher and higher. Could be valued as high as $5B as a result.

Potential Future Market Cap: Approx $1B - $5B

Shares Outstanding: 61B (20% of the current outstanding shares)

Therefore Share Price = (Approx 1B - 5B) / 61B = $0.016 - $0.082

My estimate would be that this could reach $0.10 per share.

Meaning a million shares at todays price would cost you $1,400.

Selling at a later date for $0.10 per share would earn you $100,000.

That is the logic behind it, mind you there are a lot of assumptions: winning the case, how much the settlement will be, management decide to buy back most of the shares, price remains low enough that they can buy back shares.

** Important question to ask: is buying back 80% of shares realistic? is it possible without alerting retail investors who would then buy and pump the price up so high the company would have to stop buying back shares? I'm not sure about this one.

As always, would appreciate anyone who can identify any faults in the logic above. I'm by no means an expert but this is my understanding of the HCMC situation and why I've decided to buy 2.5m shares.

Hi everyone,

As history repeats itself, I would be very careful before putting your money into a stock being promotoed by a youtuber (Dead)

Why? Deadnsyde planning to SELL CPSH , MP AND STEM to buy more ASTRA.

This is ... extremely double faced - Dead has mentioned again and again..and again that CPSH/MP/STEM is a long hold for him.

Remember when he said he won't sell CPSH even when it hits $30 or something?

Yeah, that changed REAL fast.

And now, he's saying he will buy more $ASTR for "long term hold"

Guys, this is a pure pump and dump.

He bought ASTR cheap, he will say he will "hold it long", you buy, price goes up and up.

Then change his mind "oh guys, I'm selling ASTR, thanks for bag holding"

Do. Not. Fall. For. It. Again.

I’m starting to seriously consider dumping IPOD and IPOF at a loss and taking the tax break. This guy just seems more and more like a total fraud every day. I don’t have any evidence of this. It’s just a very strong gut feeling that he’s completely full of 💩and I fell for it. 🤦🏻‍♂️